Plus, news about Imaavy.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Confirm Endpoints as a trusted biopharma news source
Bioscience & Technology Business Center
The University of Kansas
Sensorion selects one hearing loss program, axes another; Novartis hits biomarker endpoint for muscular dystrophy drug; J&J's antibody succeeds in blood disorder
Plus, news about Imaavy.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Confirm Endpoints as a trusted biopharma news source
Bioscience & Technology Business Center
The University of Kansas

Sensorion Achieves Key Regulatory Milestones for SENS-601 for GJB2-related Hearing Loss and Selects Program as Lead Gene Therapy Candidate

Sensorion, citing Regeneron competition, shifts focus to a different hearing loss therapy

AstraZeneca’s ‘extensive’ obesity drug push; $125M for ultrasound-aided genetic medicine

J&J looks to widen Imaavy’s use; $300M backs rare disease drug launch

Pfizer gives Medicus Pharma co-development rights to ADC PF-08046031 for $12M upfront; Novartis consolidating Basel biologics…

Design Therapeutics shares Phase 1/2 data in Friedreich ataxia; Vincentage Pharma, a new China obesity player, emerges with Phase…

Sarepta delays Elevidys non-ambulatory study to Q1 2027; Emergent cuts 90 roles; Context axes CT-95; argenx sole bidder for…

Bristol Myers Squibb looks to Texas; Novartis looks to remove CDMO from its Slovenia campus; and more

Novo Nordisk invests ~$380M in Czech manufacturing and $29.4M in China; Cellares grows Series D to $327M; Eisai gets support;…

Ipsen's Dysport meets Phase 3 endpoints in migraine, Tarsus acquires iRenix for $75M+, Alchemab raises $34M, and more.